What is the study about?
The Passive Immunity Trial for Our Nation (Pass It On) is a clinical trial testing a treatment for COVID-19 patients who are hospitalized. This treatment, convalescent plasma, comes from the blood of patients who have recovered from COVID-19. These patients have developed antibodies that help fight the virus and will be given to sick patients who are in the hospital. Participation in this research study is completely voluntary.

Why is this study important?
Many medications and treatments are being studied. This research study will help researchers learn if convalescent plasma helps patients with COVID-19 recover faster.

Why should patients with COVID-19 join?
Study participants may see an improvement in their condition, including survival, faster recovery time, or less need for intensive care. Society may benefit as well from learning more about the use of convalescent plasma to treat COVID-19.

Where can patients join?
This study is currently enrolling 1,000 patients at 50 locations around the United States.

Will patient’s information be safe?
Only the research team will have access to patient information, and it will be protected under a Certificate of Confidentiality and as well as having oversight from Institutional Review Boards.

Asian Americans are disproportionately impacted by COVID-19. (CDC, 2020)

Essential workers, racial and ethnic minorities, and those with underlying health conditions are being impacted the most by COVID-19. It is crucial that researchers find a treatment that helps everyone, especially people most affected by this virus.

For more information about the study, including the benefits and risks, please visit, passitonstudy.org or contact, Terri L. Edwards, Director of Research Support Services at Vanderbilt University Medical Center via email at, terri.edwards@vumc.org